Onychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
JAAD case reports - 31(2023) vom: 11. Jan., Seite 66-68 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Narayan, Neha [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 22.12.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jdcr.2022.11.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35017220X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35017220X | ||
| 003 | DE-627 | ||
| 005 | 20231226044406.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jdcr.2022.11.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1167.xml |
| 035 | |a (DE-627)NLM35017220X | ||
| 035 | |a (NLM)36505036 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Narayan, Neha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Onychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.12.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a G-protein-coupled | |
| 650 | 4 | |a GPRC5D, G protein-coupled receptor family C group 5-member D | |
| 650 | 4 | |a MM, multiple myeloma | |
| 650 | 4 | |a R/R, relapsed or refractory | |
| 650 | 4 | |a anticancer drugs | |
| 650 | 4 | |a bispecific antibody | |
| 650 | 4 | |a chemotherapeutic | |
| 650 | 4 | |a cytotoxicity | |
| 650 | 4 | |a drug effects | |
| 650 | 4 | |a immunology | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a nail diseases | |
| 650 | 4 | |a onychomadesis | |
| 650 | 4 | |a palmoplantar keratoderma | |
| 650 | 4 | |a talquetamab. | |
| 650 | 4 | |a targeted therapy | |
| 700 | 1 | |a Williams, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Lipe, Brea |e verfasserin |4 aut | |
| 700 | 1 | |a De Benedetto, Anna |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JAAD case reports |d 2015 |g 31(2023) vom: 11. Jan., Seite 66-68 |w (DE-627)NLM255357753 |x 2352-5126 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2023 |g day:11 |g month:01 |g pages:66-68 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jdcr.2022.11.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2023 |b 11 |c 01 |h 66-68 | ||